Howard Hughes Medical Institute’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-1,226
Closed -$30.5K 365
2025
Q4
$30.5K Buy
1,226
+5
+0.4% +$126 0.02% 78
2025
Q3
$31.1K Sell
1,221
-1
-0.1% -$25 0.02% 77
2025
Q2
$29.6K Buy
+1,222
New +$28.5K 0.01% 75
2016
Q3
Sell
-1,817
Closed -$61K 168
2016
Q2
$61K Sell
1,817
-9,293
-84% -$297K 0.02% 145
2016
Q1
$312K Buy
+11,110
New +$317K 0.07% 98
2015
Q1
Sell
-15,846
Closed -$468K 185
2014
Q4
$468K Buy
15,846
+1,571
+11% +$45K 0.13% 91
2014
Q3
$400K Buy
14,275
+7,513
+111% +$211K 0.09% 90
2014
Q2
$190K Sell
6,762
-44
-0.6% -$1.25K 0.03% 97
2014
Q1
$207K Buy
6,806
+423
+7% +$12.6K 0.03% 82
2013
Q4
$185K Buy
6,383
+207
+3% +$6.03K 0.03% 95
2013
Q3
$168K Sell
6,176
-242
-4% -$6.58K 0.03% 95
2013
Q2
$171K Buy
+6,418
New +$177K 0.06% 101

Other funds holding PFE

Howard Hughes Medical Institute's PFE Position: Q1 2026 in Review

Howard Hughes Medical Institute sold out of Pfizer (PFE) in Q1 2026, closing a stake of 1,226 shares — an estimated $30.5K sold.

Howard Hughes Medical Institute first reported a position in PFE in Q2 2013 and held it in 12 quarters. The position peaked at $468K in Q4 2014. 2,952 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Howard Hughes Medical Institute reported no remaining Pfizer position as of Q1 2026 after selling out during the quarter.
  • Howard Hughes Medical Institute sold 1,226 Pfizer shares in Q1 2026, an estimated $30.5K.
  • Howard Hughes Medical Institute first reported a position in Pfizer in Q2 2013 and held it in 12 quarters.
  • Howard Hughes Medical Institute's Pfizer position peaked at $468K in Q4 2014.
  • 2,952 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Howard Hughes Medical Institute's 13F filing for Q1 2026, filed 15 May 2026.